Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

ENETS Abstract Search

#4133 Clinical impact and prognosis of patients with Si-NET and bone metastases – Do they matter?

Introduction: The prevalence of bone metastases (BM) in small intestinal neuroendocrine tumors (Si-NET) ranges from 5 to 23 %.

Conference:

Presenting Author: Wedin M

Authors: Wedin M, Daskalakis K, Tiensuu Janson E, Sundin A, Wallin G,

Keywords: bone metastases, si-net, Neuroendocrine Neoplasm,

#4054 Predictive factors of persistent thrombocytopenia after 177Lu-DOTATATE in patients with neuroendocrine tumors

Introduction: Peptide Receptor Radionuclide Therapy (PRRT) is an effective and well tolerated treatment for advanced Neuroendocrine Tumors (NET). However, some Persistent Thrombocytopenia (PT) are described and may compromise further therapies and outcome.

Conference:

Presenting Author:

Authors: Oziel-Taieb S, Ferrara R, Charrier N, Maniry J, Reichert T,

Keywords: Neuroendocrine Tumor, PRRT, LuDOTATATE, Thrombocytopenia, Bone metastases, spleen,

#3776 Long-term effects of peptide receptor radionuclide therapy (PRRT) used as first-line treatment of GEP-NET – A single centre experience

Introduction: Peptide receptor radionuclide therapy (PRRT) is a well-recognized treatment option for inoperable/metastatic somatostatin receptor-positive neuroendocrine tumors (NET) currently according to guidelines used as second or third line of treatment.

Conference:

Presenting Author:

Authors: Opalinska M, Sowa-Staszczak A, Kurzyńska A, Morawiec-Sławek K, Olearska H,

Keywords: PRRT, first-line treatment, outcome, GEP-NET, NET,

#3731 Rare metastases diagnosed on 68Ga-DOTATOC-PET/CT in small intestinal and pancreatic NETs

Introduction: Neuroendocrine metastases to the orbita, heart, breast, bone, Virchow's lymph node, and pancreas are rarely encountered in small intestinal (SI-NETs) and pancreatic NETs (P-NETs).

Conference:

Presenting Author: Wedin M

Authors: Wedin M, Daskalakis K, Wallin G, Sundin A, Tiensuu Janson E,

Keywords: Neuroendocrine Neoplasm, Rare metastases, Bone metastases, breast metastases, orbita metastases, heart metastases, Lung and pleural metastases, Pancreatic metastases,

#3659 The characteristics of somatostatin receptor PET/CT in bone metastases of neuroendocrine tumors

Introduction: Bone metastasis is a poor prognostic predictor of neuroendocrine neoplasms.

Conference:

Presenting Author: Xu J

Authors: Xu J, Xu X, Song S, Chen J,

Keywords: Bone metastasis of neuroendocrine neoplasms, 68Ga-DOTATATE, 68Ga-DOTANOC, PET/CT,